Table 2. Comparison of BRAF/MEK Inhibitor Combinations.
| BRAF inhibitor | Vemurafenib | Dabrafenib | Encorafenib |
| Dose | 960 mg (240 mg tab × 4) | 150 mg (75 mg cap × 2) | 450 mg (75 mg cap × 6) |
| Frequency | q12h | q12h | Daily |
| Administration | With or without food | On an empty stomach | With or without food |
| Other considerations | Higher incidence photosensitivity QTc monitoring | Higher incidence pyrexia | High pill burden QTc monitoring |
| MEK inhibitor | Cobimetinib | Trametinib | Binimetinib |
| Dose | 60 mg (20 mg tab × 3) | 2 mg (2 mg tab × 1) | 45 mg tab (15 mg tab × 3) |
| Frequency | Daily on days 1–21 of 28-day cycle | Daily | q12h |
| Administration | With or without food | On an empty stomach | With or without food |
| Other considerations | Dosing schedule (week off) Echocardiogram monitoring | Requires refrigeration Echocardiogram monitoring | Echocardiogram monitoring |
| Total pill burden (daily) | 11 | 5 | 12 |
Note. Information from Array Biopharma Inc. (2018a, 2018b); Genentech Inc. (2018, 2020); Novartis Pharmaceuticals Corporation (2021a, 2021b).